Clinical Trial of Avasopasem in Patients With Metastatic Hormone Receptor Positive Breast Cancer With Progression on a CDK 4/6 Inhibitor and Hormonal Therapy

This study is testing a drug called avasopasem in people with hormone receptor-positive (HR+), HER2-negative metastatic breast cancer — a type of breast cancer that is fueled by estrogen or progesterone and has spread to other parts of the body — whose cancer progressed while on CDK 4/6 inhibitor therapy combined with hormonal therapy. **You may be eligible if...** - You have HR+, HER2-negative breast cancer that has spread to other parts of your body (metastatic) - Your cancer progressed on ribociclib or abemaciclib (specific CDK 4/6 inhibitors) combined with hormonal therapy - You are in adequate overall health and your organ function meets study requirements **You may NOT be eligible if...** - Your cancer progressed on palbociclib only (you must have been on ribociclib or abemaciclib) - You have uncontrolled brain metastases - You have received more than 2 prior chemotherapy regimens for metastatic disease - You have significant heart, liver, or kidney problems - You are pregnant or breastfeeding Talk to your doctor to see if this trial is right for you.